Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study
British Journal of Dermatology · 14.08.2024 · 191 (3) · 419-427
DOI: 10.1093/bjd/ljae152 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 10.04.2024. Verfasst von Keila Mitsunaga und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Mycosis Fungoides, Interferon-alpha, Recombinant Proteins, Skin Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Background
Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon (IFN)-α (subtypes 2a and 2b) has been used to treat MF/SS since 1984; however, its production was recently stopped. The recombinant pegylated (PEG) form of IFN-α-2a remains the only alternative IFN treatment, although it has not been approved for use in MF/SS.
Objectives
To assess the effectiveness and safety of PEG-IFN-α-2a in monotherapy and in combination with other treatments using time to next treatment (TTNT) as a measure of clinical therapeutic benefit in a real-world setting.
Methods
We conducted an international, multicentre retrospective study of patients with MF and SS (of any stage) treated with PEG-IFN-α-2a from July 2012 to February 2022. Patients were included across 11 centres in 10 countries. The primary endpoints were to determine the TTNT of PEG-IFN-α-2a and adverse events (AEs) in MF/SS.
Results
In total, 105 patients were included [mean (SD) age 61 (13.1) years]; 42 (40.0%) had stage IA–IIA and 63 (60.0%) had stage IIB–IVB disease. PEG-IFN-α-2a was combined with other therapies in 67 (63.8%) patients, most commonly with extracorporeal photopheresis (36%) and bexarotene (22%). Patients with stage I–IIA disease achieved an overall response rate (ORR) of 57%; the ORR in those with stage IIB–IVB disease was 51%. Combination treatment resulted in a median TTNT of 10.4 months (range 0.6–50.7) vs. 7.0 months (range 0.7–52.4) for those who received monotherapy (P < 0.01). Overall, the mean (SD) TTNT was 9.2 (10.6) months and the ORR was 53.3% (n = 56). A complete response was seen in 13% of patients and a partial response in 40%. AEs were described in 68.6% (n = 72) of patients. Flu-like symptoms (n = 28; 26.7%), lymphopenia (n = 24; 22.9%) and elevated liver function (n = 10; 9.5%) were the most frequently reported. Grade 3–4 AEs were reported in 23 (21.9%) patients, mostly related to myelosuppression.
Conclusions
PEG-IFN-α-2a for MF/SS resulted in an ORR of 53.3% and a mean (SD) TTNT of 9.2 (10.6) months. Combination regimens were superior to monotherapy and doses of 180 µg PEG-IFN-α-2a weekly were related to a higher ORR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Dermatology, Université Paris Cité, Saint-Louis Hospital, Paris, France.
- Department of Dermatology, University Hospital Zurich and Faculty of Medicine, Zurich, Switzerland.
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland.
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Keila Mitsunaga, Marie Beylot-Barry
Zitieren
APA
Mitsunaga, K., Bagot, M., Ram-Wolff, C., Guenova, E., von Gugelberg, C., Hodak, E., Amitay-Laish, I., Papadavid, E., Jonak, C., Porkert, S., Scarisbrick, J., Applewaite, R., Beylot-Barry, M., Nicolay, J., Quaglino, P., Sanches, J. A., Cury-Martins, J., Lora-Pablos, D., & Ortiz, P. (2024). Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study. British Journal of Dermatology, 191(3), 419-427. https://doi.org/10.1093/bjd/ljae152
Vancouver
Mitsunaga K, Bagot M, Ram-Wolff C, Guenova E, von Gugelberg C, Hodak E, et al. Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study. British Journal of Dermatology. 2024;191(3):419-427. doi:10.1093/bjd/ljae152
BibTeX
@article{Mitsunaga2024,
author = {Mitsunaga, Keila and Bagot, Martine and Ram-Wolff, Caroline and Guenova, Emmanuella and von Gugelberg, Christina and Hodak, Emmilia and Amitay-Laish, Iris and Papadavid, Evangelia and Jonak, Constanze and Porkert, Stefanie and Scarisbrick, Julia and Applewaite, Rona and Beylot-Barry, Marie and Nicolay, Jan and Quaglino, Pietro and Sanches, José Antonio and Cury-Martins, Jade and Lora-Pablos, David and Ortiz, Pablo},
title = {Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study},
journal = {British Journal of Dermatology},
year = {2024},
volume = {191},
number = {3},
pages = {419--427},
doi = {10.1093/bjd/ljae152}
}
EUVIMED